Cardiome Pharma (CRME) Tops Q1 EPS by 7c

Cardiome Pharma (NASDAQ: CRME) reported Q1 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $7.48 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• BWS Financial Starts Capstone Energy Plus (CEPL) at Buy
• PBF Energy (PBF) PT Raised to $57 at Mizuho